MX2015011462A - Vesiculas colestosomicas para incorporacion de moleculas en quilomicrones. - Google Patents
Vesiculas colestosomicas para incorporacion de moleculas en quilomicrones.Info
- Publication number
- MX2015011462A MX2015011462A MX2015011462A MX2015011462A MX2015011462A MX 2015011462 A MX2015011462 A MX 2015011462A MX 2015011462 A MX2015011462 A MX 2015011462A MX 2015011462 A MX2015011462 A MX 2015011462A MX 2015011462 A MX2015011462 A MX 2015011462A
- Authority
- MX
- Mexico
- Prior art keywords
- cholestosome
- loaded
- present
- patient
- molecules
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Dispersion Chemistry (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
Abstract
La presente invención está dirigida a una nanopartícula de éster de colesterilo portadora de carga, con un compartimento hueco (cholestosome: colestosoma), que esencialmente consiste en al menos un éster de colesterilo no iónico y una o más moléculas activas encapsuladas, el cual no puede pasar apreciablemente a través de una membrana enterocítica en ausencia de la molécula que se carga en el colestosoma, el colestosoma tiene una superficie neutra y la capacidad de pasar a los enterocitos como lo hacen los lípidos nutrientes absorbidos por vía oral que utilizan las vías celulares para llegar al aparato de Golgi. Según la presente invención, los nuevos colestosomas portadores de carga según la presente invención, tienen la capacidad de depositar moléculas activas dentro de las células de un paciente o de un individuo y realizar tratamiento o diagnóstico en el paciente o el individuo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361783003P | 2013-03-14 | 2013-03-14 | |
PCT/US2014/027761 WO2014152795A2 (en) | 2013-03-14 | 2014-03-14 | Cholestosome vesicles for incorporation of molecules into chylomicrons |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015011462A true MX2015011462A (es) | 2016-05-31 |
Family
ID=51581747
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015011462A MX2015011462A (es) | 2013-03-14 | 2014-03-14 | Vesiculas colestosomicas para incorporacion de moleculas en quilomicrones. |
Country Status (11)
Country | Link |
---|---|
US (5) | US9693968B2 (es) |
EP (1) | EP2970369B1 (es) |
JP (2) | JP2016513712A (es) |
CN (1) | CN105164143B (es) |
AU (1) | AU2014236559B2 (es) |
BR (1) | BR112015022936A2 (es) |
CA (1) | CA2905108C (es) |
HK (1) | HK1212354A1 (es) |
IL (1) | IL241501B (es) |
MX (1) | MX2015011462A (es) |
WO (1) | WO2014152795A2 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9119782B2 (en) | 2006-03-20 | 2015-09-01 | Mary P. McCourt | Drug delivery means |
US20180099001A1 (en) | 2011-04-29 | 2018-04-12 | Volant Holdings Gmbh | Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof |
US9693968B2 (en) * | 2013-03-14 | 2017-07-04 | Jerome J. Schentag | Cholestosome vesicles for incorporation of molecules into chylomicrons |
CA2919268C (en) | 2013-07-25 | 2023-09-05 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
US10260067B2 (en) | 2014-10-01 | 2019-04-16 | The Brigham And Women's Hospital, Inc. | Enhancing dermal wound healing by downregulating microRNA-26a |
ES2574615B1 (es) * | 2014-12-19 | 2017-07-24 | Biopraxis Research Aie | Nanopartícula lipídica de tobramicina |
ES2968038T3 (es) | 2015-12-23 | 2024-05-06 | Univ Johns Hopkins | Agonista GLP-1R de acción prolongada como terapia de afecciones neurológicas y neurodegenerativas |
CN105797132A (zh) * | 2016-05-03 | 2016-07-27 | 滨州医学院 | 沙奎拉韦的医药新用途 |
CN110418636A (zh) * | 2016-08-23 | 2019-11-05 | 杰罗米.J.申塔格 | 将肽、蛋白质和核酸负载至乳糜微粒和体细胞中的胆固醇酯囊泡 |
US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
CN107260681A (zh) * | 2017-08-04 | 2017-10-20 | 济南维瑞医药科技开发有限公司 | 一种磷酸特地唑胺脂质体的制备方法及其应用 |
WO2019032877A1 (en) * | 2017-08-09 | 2019-02-14 | Arizona Board Of Regents On Behalf Of The University Of Arizona | MICELLES AND VESICLES FOR RELEASE OF GLYCOPEPTIDES |
CN109929806B (zh) * | 2017-12-19 | 2020-05-08 | 北京吉源生物科技有限公司 | 一种表达glp1和fgf21的干细胞及其用途 |
BR112020014596A2 (pt) | 2018-01-23 | 2020-12-08 | Gila Therapeutics, Inc. | Formulações, composições e métodos farmacêuticos de peptídeo yy |
EP3768829A4 (en) * | 2018-02-01 | 2022-02-09 | The Royal Institution for the Advancement of Learning / McGill University | FORMULATIONS TO ENHANCE DELIVERY OF HYDROPHOBIC AGENTS |
WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
KR20210149157A (ko) * | 2019-05-14 | 2021-12-08 | 파모사 바이오팜 인코포레이티드 | 약산성 약물의 약제학적 조성물 및 투여 방법 |
CN110638788A (zh) * | 2019-10-25 | 2020-01-03 | 广州医科大学 | 一种能够沉默Pcsk9蛋白的siRNA、其纳米递送系统及应用 |
BR112022025381A2 (pt) | 2020-06-11 | 2023-01-24 | Provention Bio Inc | Métodos e composições para prevenir diabetes tipo 1 |
JP2023543037A (ja) * | 2020-09-25 | 2023-10-12 | アルゴリズム サイエンシズ,インコーポレイテッド | 血管拡張剤送達のための組成物及び方法 |
JP7505831B2 (ja) * | 2021-12-14 | 2024-06-25 | シード医療製薬株式会社 | 海藻抽出物を含む高血圧症改善剤並びに同高血圧症改善剤を含む機能性食品、医薬部外品及び医薬品 |
CN114470186B (zh) * | 2022-02-17 | 2023-10-20 | 唐颐控股(深圳)有限公司 | 一种可吸入式纳米新冠疫苗的制备方法 |
US11951177B2 (en) | 2022-03-23 | 2024-04-09 | Nanovation Therapeutics Inc. | High sterol-containing lipid nanoparticles |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US5231112A (en) | 1984-04-12 | 1993-07-27 | The Liposome Company, Inc. | Compositions containing tris salt of cholesterol hemisuccinate and antifungal |
ATE77051T1 (de) | 1988-03-04 | 1992-06-15 | Takeda Chemical Industries Ltd | Liposom-zusammensetzung. |
US4906476A (en) | 1988-12-14 | 1990-03-06 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs in lungs |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
WO1992003123A1 (en) | 1990-08-28 | 1992-03-05 | Liposome Technology, Inc. | Liposome alternative bilayer formulations |
US5874560A (en) | 1994-04-22 | 1999-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Melanoma antigens and their use in diagnostic and therapeutic methods |
US7001614B2 (en) | 1996-08-19 | 2006-02-21 | The United States Of America As Represented By The Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
SI0937456T1 (en) | 1998-02-23 | 2004-12-31 | Cilag Ag International | Erythropoietin liposomal dispersion |
JP4255123B2 (ja) | 2002-04-26 | 2009-04-15 | アンジェスMg株式会社 | 転写dna結合部位を含む環状ダンベルデコイオリゴデオキシヌクレオチド(cdodn) |
CA2752143C (en) * | 2002-05-15 | 2014-09-23 | Sutter West Bay Hospitals | Delivery of nucleic acid-like compounds |
AU2003225369A1 (en) | 2003-04-11 | 2004-11-01 | Coreana Cosmetics Co., Ltd. | Medicinal cosmetical composition with areca catechu seed extract |
CA2524368A1 (en) | 2003-05-02 | 2004-11-18 | The Board Of Trustees Of The University Of Illinois | Biodegradable nanoparticles comprising an aminoglycoside and a polymer like a polysaccharide |
JP2007501850A (ja) | 2003-05-09 | 2007-02-01 | ノボソム アーゲー | 作用物質のデリバリーのための注射可能なリポソーム式デポー製剤 |
CN101031287A (zh) * | 2004-03-02 | 2007-09-05 | 麻省理工学院 | 纳米细胞药物递送系统 |
US7662405B2 (en) | 2005-08-09 | 2010-02-16 | The Research Foundation Of State University Of New York | Compositions and methods of preparation of liposomal microparticulate IL-12 |
US9119782B2 (en) | 2006-03-20 | 2015-09-01 | Mary P. McCourt | Drug delivery means |
US20100080773A1 (en) * | 2008-09-26 | 2010-04-01 | Sdg, Inc. | Orally Bioavailable Lipid-Based Constructs |
US20100297242A1 (en) * | 2007-10-17 | 2010-11-25 | Tae-Gwan Park | Ldl-like cationic nanoparticles for deliverying nucleic acid gene, method for preparing thereof and method for deliverying nucleic acid gene using the same |
ES2645588T3 (es) * | 2008-05-05 | 2017-12-05 | Oramed Ltd. | Métodos y composiciones para la administración oral de exenatida |
DK2851084T3 (en) * | 2008-05-22 | 2018-07-30 | H Lundbeck As | Modulation of Vps10p domain receptors for the treatment of cardiovascular disease |
WO2010027498A2 (en) | 2008-09-03 | 2010-03-11 | New Science Holdings, Llc | Compositions and methods for inducing satiety and treating non-insulin dependent diabetes emillitus, pre-diabetic symptoms, insulin resistance and related disease states and conditions |
US9757346B2 (en) | 2008-09-03 | 2017-09-12 | Volant Holdings Gmbh | Compositions and methods for treating insulin resistance and non-insulin dependent diabetes mellitus (type II diabetes) |
JP2009143963A (ja) | 2009-03-25 | 2009-07-02 | Sinan Tas | 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ/スムーズンド信号を使用する腫瘍を治療するための製薬組成物 |
US20130273154A1 (en) | 2011-03-02 | 2013-10-17 | Joseph M. Fayad | Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes |
SG184127A1 (en) | 2010-03-19 | 2012-10-30 | Massachusetts Inst Technology | Lipid vesicle compositions and methods of use |
US20110268653A1 (en) | 2010-04-16 | 2011-11-03 | The Board Of Regents Of The University Of Texas System | Compositions and Methods Related to Acid Stable Lipid Nanospheres |
US8355188B2 (en) | 2010-07-27 | 2013-01-15 | Foxlink Image Technology Co., Ltd. | Document guiding mechanism |
KR20190060879A (ko) | 2011-03-02 | 2019-06-03 | 제롬 쉔타그 | 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단 |
EP2709590A4 (en) * | 2011-05-11 | 2015-05-13 | Nanovalent Pharmaceuticals Inc | REINFORCED GROWTH INHIBITION OF OSTEOSARCOMS THROUGH CYTOTOXIC POLYMERIZED LIPOSOMAL NANOPARTICLES TO AIM AT THE ALCAM CELL SURFACE RECEPTOR |
US9693969B2 (en) | 2012-01-02 | 2017-07-04 | Andrew L. SKIGEN | Mucous membrane active agent application |
JP6203816B2 (ja) | 2012-03-29 | 2017-09-27 | セラバイオーム,エルエルシー | 回腸及び虫垂に対して活性の胃腸部位特異的経口ワクチン接種製剤 |
US9693968B2 (en) * | 2013-03-14 | 2017-07-04 | Jerome J. Schentag | Cholestosome vesicles for incorporation of molecules into chylomicrons |
RU2663127C2 (ru) | 2013-03-15 | 2018-08-01 | Олтек, Инк. | Селенсодержащие композиции и их применение для лечения и предотвращения заболеваний или состояний, связанных с митохондриальной дисфункцией |
WO2016155809A1 (en) | 2015-03-31 | 2016-10-06 | Biontech Rna Pharmaceuticals Gmbh | Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell |
CN110418636A (zh) | 2016-08-23 | 2019-11-05 | 杰罗米.J.申塔格 | 将肽、蛋白质和核酸负载至乳糜微粒和体细胞中的胆固醇酯囊泡 |
-
2014
- 2014-03-14 US US14/776,308 patent/US9693968B2/en active Active - Reinstated
- 2014-03-14 EP EP14769286.7A patent/EP2970369B1/en active Active
- 2014-03-14 JP JP2016502534A patent/JP2016513712A/ja not_active Ceased
- 2014-03-14 MX MX2015011462A patent/MX2015011462A/es unknown
- 2014-03-14 WO PCT/US2014/027761 patent/WO2014152795A2/en active Application Filing
- 2014-03-14 CA CA2905108A patent/CA2905108C/en active Active
- 2014-03-14 AU AU2014236559A patent/AU2014236559B2/en active Active
- 2014-03-14 CN CN201480025264.0A patent/CN105164143B/zh active Active
- 2014-03-14 BR BR112015022936A patent/BR112015022936A2/pt not_active Application Discontinuation
-
2015
- 2015-09-10 IL IL241501A patent/IL241501B/en active IP Right Grant
-
2016
- 2016-01-11 HK HK16100237.5A patent/HK1212354A1/xx unknown
-
2017
- 2017-05-24 US US15/603,992 patent/US10369114B2/en active Active
-
2019
- 2019-01-17 JP JP2019005894A patent/JP6688408B2/ja active Active
- 2019-07-31 US US16/527,579 patent/US11052052B2/en active Active
-
2021
- 2021-06-02 US US17/337,283 patent/US11633364B2/en active Active
-
2023
- 2023-03-24 US US18/126,251 patent/US12005146B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2905108A1 (en) | 2014-09-25 |
US10369114B2 (en) | 2019-08-06 |
IL241501A0 (en) | 2015-11-30 |
EP2970369B1 (en) | 2023-11-22 |
US11633364B2 (en) | 2023-04-25 |
US20230277471A1 (en) | 2023-09-07 |
AU2014236559A1 (en) | 2018-05-24 |
CN105164143A (zh) | 2015-12-16 |
CN105164143B (zh) | 2019-02-19 |
EP2970369A4 (en) | 2016-10-12 |
CA2905108C (en) | 2021-12-07 |
JP2019070031A (ja) | 2019-05-09 |
WO2014152795A3 (en) | 2014-11-27 |
JP6688408B2 (ja) | 2020-04-28 |
EP2970369A2 (en) | 2016-01-20 |
US20180055780A1 (en) | 2018-03-01 |
BR112015022936A2 (pt) | 2017-07-18 |
AU2014236559B2 (en) | 2020-03-12 |
US12005146B2 (en) | 2024-06-11 |
US20220040116A1 (en) | 2022-02-10 |
US20200069598A1 (en) | 2020-03-05 |
US20160030361A1 (en) | 2016-02-04 |
HK1212354A1 (en) | 2016-06-10 |
JP2016513712A (ja) | 2016-05-16 |
US9693968B2 (en) | 2017-07-04 |
WO2014152795A2 (en) | 2014-09-25 |
US11052052B2 (en) | 2021-07-06 |
IL241501B (en) | 2020-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015011462A (es) | Vesiculas colestosomicas para incorporacion de moleculas en quilomicrones. | |
WO2012083185A3 (en) | Peptide-based in vivo sirna delivery system | |
WO2014170389A8 (en) | Enhanced adoptive cell therapy | |
WO2012122544A3 (en) | Protein nanoparticle dispersions | |
MX2016006988A (es) | Nuevos peptidos hidrofobos ultracortos que se autoensamblan en hidrogeles nanofibrosos y sus usos. | |
EP4357083A3 (en) | Single site robotic device and related systems and methods | |
WO2015095624A3 (en) | Drug mixing and delivery system and method | |
MX2013001636A (es) | Composiciones y metodos para el tratamiento de taupatias | |
WO2013084000A3 (en) | Exosomes for delivery of biotherapeutics | |
WO2015059180A3 (en) | Upconverting vesicles and uses | |
BR112015003794A2 (pt) | partículas funcionalizadas do grupo iva e métodos de uso destas | |
AU2018205186B2 (en) | Angiotensin in treating brain conditions | |
WO2013090523A3 (en) | Methods, systems, and compositions for cell-derived/vesicle-based microrna delivery | |
WO2013136189A3 (en) | Methods and materials for treatment of pompe's disease | |
MX359004B (es) | Método para la fabricación de células madre que tienen tamaño apropiado para administración intravascular. | |
WO2013111012A3 (en) | Methods and compositions for therapeutic agents | |
WO2012040331A3 (en) | Multistage nanoparticles | |
WO2014113704A3 (en) | Enhanced differentiation of mesenchymal stem cells | |
IN2015DN00344A (es) | ||
WO2010086838A3 (en) | Non-ad5 adenoviral vectors and methods and uses related thereto | |
WO2014039741A3 (en) | Treatments for melanoma | |
WO2013109190A3 (en) | Cho-gmt recombinant protein expression | |
GB2491079A (en) | Air intake structure | |
WO2019133454A3 (en) | Methods to improve the therapeutic index of activated t cells | |
MX2015005992A (es) | Metodo mejorado para la preparacion de la vincristina liposomal encapsulada para el uso terapeutico. |